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Keutel syndrome (KS) is a rare autosomal recessive genetic disorder that was first
identified in the beginning of the 1970s and nearly 30 years later attributed to loss-
of-function mutations in the gene coding for the matrix Gla protein (MGP). Patients with
KS are usually diagnosed during childhood (early onset of the disease), and the major
traits include abnormal calcification of cartilaginous tissues resulting in or associated with
malformations of skeletal tissues (e.g., midface hypoplasia and brachytelephalangism)
and cardiovascular defects (e.g., congenital heart defect, peripheral pulmonary artery
stenosis, and, in some cases, arterial calcification), and also hearing loss and mild
developmental delay. While studies on Mgp−/− mouse, a faithful model of KS, show that
pathologic mineral deposition (ectopic calcification) in cartilaginous and vascular tissues
is the primary cause underlying many of these abnormalities, the mechanisms explaining
how MGP prevents abnormal calcification remain poorly understood. This has negative
implication for the development of a cure for KS. Indeed, at present, only symptomatic
treatments are available to treat hypertension and respiratory complications occurring in
the KS patients. In this review, we summarize the results published in the last 50 years on
Keutel syndrome and present the current status of the knowledge on this rare pathology.
Keywords: recessive genetic disorder, matrix Gla protein, abnormal calcification, cartilaginous tissues, mouse
model, gamma-carboxylation, phosphorylation
INTRODUCTION
Keutel syndrome (KS; OMIM #245150; ORPHANET #85202) was first described in 1971 in
two consanguineous siblings (Keutel et al., 1971; Figure 1A). It is an extremely rare autosomal
recessive disorder (estimated prevalence of 1 in 1,000,000), which is usually diagnosed during
childhood, although it can remain undetected until adulthood. Forty-two cases have been reported
so far, with half in Turkish population (Table 1). However, this number may be underestimated
as the main clinical characteristics of KS – midface hypoplasia, abnormal cartilage calcification,
brachytelephalangism, peripheral pulmonary stenosis – are also observed in other disorders (for
example, chondrodysplasia punctata or Conradi’s disease), leading to the misdiagnosis of some
forms of KS into another disease (Say et al., 1973). Moreover, reports of mild cases of KS and
intrafamilial phenotypic variability (Tüysüz et al., 2015; cases 36 and 37 in Table 1) indicate that
some patients may have undetectable forms of the disease. Although parental consanguinity is
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prevalent in KS, pregnancy is normal (except for one reported
case of repeated miscarriages) and blood parameters, including
calcium and phosphate serum levels, are usually unremarkable.
The prognosis of KS is good in most patients and their life
expectancy mostly depends on the severity of the pulmonary
complications. In 1999, almost 30 years after its first description,
the pathogenesis of KS was associated with a non-functional
matrix Gla protein (Munroe et al., 1999; Figure 1A), an
extracellular matrix (ECM) protein known to function as an
inhibitor of tissue calcification (Luo et al., 1997). This discovery
allowed a better understanding of the mechanisms underlying
this disease and identified a target for a possible therapeutic
solution, although much remains to be done.
In this short review that marks the 50 years of the
discovery of Keutel syndrome, we will describe the main clinical
characteristics of KS, give an overview on the mutations identified
in MGP gene and present data collected from knockout and
transgenic mouse models that help us to understand KS-
associated pathologies.
DESCRIPTION OF THE DISEASE
The clinical traits of KS are very diverse (Table 1), and each
is highly variable in its severity and occurrence. Yet, the most
consistent traits in this disorder are: (i) dysmorphic facial
abnormalities including sloping forehead, midface hypoplasia,
depressed nasal bridge and hypoplastic alae nasi, receding chin
and sometimes short palate; (ii) abnormal cartilage calcification
in the larynx, the respiratory tract, the ears, the nose and the
ribs; and (iii) brachytelephalangism that, in around 75% of the
cases, is characterized by shortening and broadening of the first to
fourth distal phalanges (punctate epiphyses), with sparing of the
fifth phalange, although different combinations have been found
sporadically in some patients and without systematic bilaterality
(Miller, 2003). Additional symptoms found in almost all patients
include multiple peripheral pulmonary artery stenoses, mild
to severe unilateral or bilateral sensorineural, mixed hearing
loss, and intellectual disability that ranges from borderline
intelligence to mild developmental delay, short stature, and
respiratory conditions including dyspnea, wheezing, cough, and
infections (Table 1). Other inconsistent symptoms are also
observed in isolated individuals affected by KS such as seizures
or epileptic events (Teebi et al., 1998; Hur et al., 2005), otitis
media and/or sinusitis, dental malocclusion, and cardiovascular
defects such as ventricular septum defects and ventricular
hypertrophy (Table 1).
Long-term follow-up studies revealed additional features in
aging KS patients (Table 1). After 30 years of age, KS patients
typically develop skin lesions (Meier et al., 2001; Hur et al.,
2005; Nanda et al., 2006), although this has been subject
of debate regarding the definite cause and definition of the
skin defects observed in these patients (Hur et al., 2005;
Cohen and Boyadjiev, 2006; Nanda et al., 2006). Transient
patchy alopecia has also been reported in the follow-up of
a patient initially described by Fryns et al. (Devriendt et al.,
1999) and later confirmed in another case (Acar et al., 2010;
Weaver et al., 2014). Interestingly, vascular calcification has
been reported in only a few cases. In this regard, post-mortem
examination of the youngest sibling originally described by
Keutel uncovered calcification of pulmonary, coronary, hepatic,
renal, meningeal and cerebral arteries (Cranenburg et al., 2011).
Aortic calcification and intracranial-brain calcification have also
been observed in a few other KS patients (Teebi et al., 1998;
Ayyildiz et al., 2012; Bosemani et al., 2014; Weaver et al., 2014).
Most of the symptoms seen in KS are thought to be secondary
to calcifications. Intracranial calcification could explain seizure,
epilepsy, and even developmental delay. Tracheobronchial
calcification could be responsible for dyspnea and cough by
inducing trachea and bronchi stenoses and reducing respiratory
tract elasticity. Finally, auricular calcification, sometimes leading
to petrified ears of the pinnae or ligamentous calcification of
the ossicles, could explain the hearing loss in KS patients,
although frequent respiratory infections could also be a cause
of the auditory defects. Finally, systemic hypertension found
in most young patients and commonly controlled by standard
antihypertensive medication is thought to be due to renal arterial
microcalcification (Khosroshahi et al., 2014).
Some of the traits listed above for KS overlap with those
found in other rare congenital or acquired diseases, including
brachytelephalangic X-linked chondrodysplasia punctata
(CDPX1; Maroteaux, 1989; Weaver et al., 2014), vitamin
K-dependent gamma-glutamyl carboxylase (GGCX) mutation
disorders (Tie et al., 2016), vitamin K deficiency embryopathy
(Menger et al., 1997), warfarin embryopathy (Struwe et al.,
1984; Kumar et al., 2012), or warfarin sodium therapy-induced
complications (Moncada et al., 1992). Although it is likely that
several of these diseases may involve functional alterations
of the vitamin K-dependent activity of MGP, the exhaustive
characterization of the reported KS patients (Table 1) now
unequivocally recognizes KS as a separate disease that can
be readily distinguished on the basis of morphological and
clinical exams and further confirmed by genetic testing (MGP
sequencing). This should help for better detection and care for KS
patients whose prognosis is usually reasonably good. Recurrent
cough and wheezing episodes as well as upper respiratory
tract infections or seizures often lead to hospitalization and
the incidental diagnosis of KS by chest radiograph. In fact,
life expectancy of the patients mainly depends on the severity
of their respiratory complications, which are usually treated
symptomatically using antibiotics to prevent infections (Meier
et al., 2001) and corticosteroids or inhalative bronchodilating
drugs to improve the respiratory functions (Devriendt et al.,
1999; Özdemir et al., 2006; Girit and Senol, 2019). However, such
treatments are not always efficient (Meier et al., 2001; Cranenburg
et al., 2011). Interestingly a vitamin K1 supplementation strategy
was tried in a unique KS patient, where the presence of
undercarboxylated MGP was characterized. However, this
was found to be ineffective in increasing MGP carboxylation
(Cranenburg et al., 2011). If patients have cosmetic complaints,
plastic and reconstructive surgeries can be offered, e.g., nose
grafting (Ciloglu et al., 2015). Although it has not been done so
far, exploratory middle ear surgery could be considered for KS
patients with conductive hearing loss (Acar et al., 2010).
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FIGURE 1 | Literature timeline for Keutel syndrome (KS) and matrix Gla protein (MGP) (A). MGP gene and protein structure mapping the eight mutations associated
with KS (B). Most common traits observed in KS patients genotyped for MGP (C).
IDENTIFICATION OF THE CAUSAL GENE
Matrix Gla protein is a vitamin K-dependent protein originally
isolated from bovine bone (Price et al., 1983; Price and
Williamson, 1985) and later found to be mainly expressed
by chondrocytes and cardiovascular cells (Hale et al., 1988;
Yao et al., 2007; Chiyoya et al., 2018). The human protein
contains 84 residues and a complex molecular structure including
a signal peptide required for its secretion into the ECM, a
phosphorylation motif containing three serine residues located
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at the N-terminal end of the mature protein, separated from the
remaining protein regions by a cleavage site (AXXF) followed
by a γ-carboxylase recognition site and a Gla domain. It
also contains a disulfide bridge between two cysteines and
a C-terminal RR cleavage site (summarized in Figure 1B).
The posttranslational modification of five glutamic acid (Glu)
residues (see localization in Figure 1B) into γ-carboxyglutamic
acid (Gla) residues is thought to be central to MGP function
and requires the GGCX activity with vitamin K as a cofactor
(Engelke et al., 1991). Although MGP is often considered to
be fully active when phosphorylated and carboxylated, other
forms (i.e., under-carboxylated or non-phosphorylated MGP)
have been shown to have some clinical relevance, in particular
for vascular calcification (Schurgers et al., 2010; Roumeliotis
et al., 2019). MGP anti-mineralization action is currently not
fully understood, although several mechanisms have already been
proposed, e.g., its high affinity for calcium ions and calcium-
phosphate crystals through the Gla residues would prevent
mineral deposition or stimulate phagocytosis by macrophages,
and its binding to BMP-2 would prevent the trans-differentiation
of vascular smooth muscle cells into osteoblasts (see Roumeliotis
et al., 2020 and references therein).
MGP structure has been remarkably conserved throughout
evolution since its appearance 400 million years ago during the
onset of cartilaginous structures, indicating that MGP plays a
central function in vertebrates (Cancela et al., 2014). The human
MGP gene was first sequenced in 1990 and localized in human
chromosome 12p12.3-13.1 (Cancela et al., 1990). It was found
to span four exons and it appears to be a single copy gene in
all species identified to date. More recently, an additional exon
was identified in single-pass cDNA sequences from human fetal
brain precursor tissue (Cancela et al., 2014), bringing the total
number of exons to five and adding 33 amino acid residues
in frame with the previous protein. This new exon is specific
to primates, is located between previously identified exons one
and two and suffers alternative splicing in most tissues analyzed
so far. Even though MGP gene was identified 30 years ago, its
regulation is still unclear and much remains to be uncovered.
So far, MGP was found to be regulated in human by retinoic
acid (Kirfel et al., 1997) and FGF (Stheneur et al., 2003) and,
more recently, by epigenetic mechanisms (Tiago et al., 2016;
Tuo and Ye, 2017). In mouse, parathyroid hormone regulates
Mgp expression through the transcription factors Sp and Runx2
(Suttamanatwong et al., 2009). In 1997, the development of a
knockout (KO) mouse model for MGP provided crucial clues
toward understanding the function of this enigmatic protein,
until then without a significant physiological function (Luo
et al., 1997). Its role as a physiological inhibitor of calcification
was further consolidated in the next few years when it was
identified as KS causal gene (Munroe et al., 1999). A genome
search using homozygosity mapping provided evidence of the
linkage of KS to the human chromosomal region 12p12.3-13.1
(maximum multipoint lod score, 4.06), where MGP gene is
located, and the common traits displayed in both KS patients
and the KO mice, including abnormal calcification of cartilage
affecting auricles, nose, and respiratory tract, further supported
the central role of MGP in this disease. Previously, Teebi
et al. (1998) had provided evidence supporting the fact that
KS was most likely due to an autosomal recessive inheritance.
In the same year, Yagami et al. (1999) provided additional
evidence for the function of MGP as a calcification inhibitor
by overexpressing this protein in osteoblasts in the developing
chick limbs resulting in a severe decrease in ECM mineralization
and endochondral ossification. In the following two decades,
eight different mutations in the MGP gene were identified in
KS patients, all of them severely affecting protein structure
and probably protein function (Figure 1B) and likely to be
responsible for all or part of the phenotypes observed in KS
patients (Figure 1C).
KNOCKOUT AND TRANSGENIC MOUSE
MODELS TO UNDERSTAND THE
PATHOLOGIES OF KS
Matrix Gla protein knockout (Mgp−/−) mice generated by Dr.
Karsenty’s group is a widely used model for KS (Luo et al., 1997).
These mice faithfully recapitulate most of the traits seen in the
human patients, which include the widespread calcification of
various cartilaginous tissues and associated skeletal anomalies.
In addition, these mice display severe vascular calcification (Luo
et al., 1997; Murshed et al., 2004; Leroux-Berger et al., 2011;
Khavandgar et al., 2014), a trait that has only been reported in a
limited number of KS patients (Cranenburg et al., 2011; Ayyildiz
et al., 2012; Bosemani et al., 2014; Weaver et al., 2014). Unlike
KS patients who are unaffected or mildly affected by vascular
calcification, all Mgp−/− mice die before two months of age
due to complications (aortic rupture and hemorrhage) caused by
severe vascular calcification (Luo et al., 1997).
The major cartilaginous tissues prematurely/abnormally
mineralized in Mgp−/− mice are trachea, nasal septum and
growth plates, including the spheno-occipital synchondrosis
(SOS) in the head (Marulanda et al., 2017). Interestingly,
calcification of different cartilaginous tissues in MGP-deficient
mice does not appear at the same time. The early calcium
phosphate minerals in the nasal septum cartilage can be detected
by histological methods by the end of the first week after birth
(Marulanda et al., 2017). Most of the deposited minerals at
this stage are amorphous calcium phosphate. The amount of
minerals progressively increases over time and by the end of six
weeks, septal cartilage appears to be fully mineralized. Almost
simultaneously progressive deposition of minerals starts in the
SOS at the cranial base, where mineral deposition occurs at the
cartilaginous ECM of the synchondrosis leading to its premature
closure (Marulanda et al., 2017). Abnormal calcification of the
tracheal cartilage in Mgp−/− mice is seen after the third week,
while the growth plate cartilage in the long bones starts calcifying
during the second month after birth (Marulanda et al., 2013).
As in KS patients, the premature and/or abnormal calcification
of the cartilaginous tissues has profound effects on the
development of the skeletal traits in Mgp−/− mice. In-
depth analyses of these traits in various mouse models have
tremendously helped our understanding of the mechanisms
causing general skeletal traits in KS, such as midface hypoplasia


















TABLE 1 | Clinical characteristics of Keutel syndrome.
Case no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
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11 8 7 13 13 31/2 14 11 10 8 8 2
months
15 14 21 − 4 4 4 5
Gender ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♀ ♀ ♀ ♂ ♂ ♂ ♂ ♂ ♀ ♂ ♀ ♀ ♂
Country of
origin
Turkey Turkey Morocco Belgium − Turkey Saudi
Arabia
− Palestine − Turkey Spain
France
Turkey − −
Consanguinity    −       − #  − −  #  − −
Brachytele-
phalangism
               −     
Cartilage
calcification
               −   − −
Facial features −               −   − −
PPS/cardiac
defects
  − #  #       #   − #  − −
Short stature # #  −  # # #  #  −  − − − # # − −
Developmental
delay
# # # −  # # # # #    − − −  # − −
Hearing loss      −          −  − − −
Seizures #  − − −  # # # # − −  − − − − − − −
Respiratory
problems
            # − − − −  − −
Vascular
calcification
#  − − − − − − − − − − − − − − − − − −
Others Dental
impairment
Alopecia Skin lesions, severe hypertension Myopia Miscarriage








































TABLE 1 | Continued
Case no. 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42


















































8 6 3 4 7 9 31 16 6 New-born 8 months 2 35 29 20 13 22 20 26 13 14 3 months





Turkey Turkey Turkey Turkey East Asia Kuwait Turkey Kuwait Turkey Turkey Turkey Brazil Turkey Morocco
Consanguinity          # −       −     
Brachytele
phalangism
           −  #    −   −  
Cartilage
calcification
           −      −     
Facial features        #    −     #      
PPS/cardiac
defects
 #  #   #     −      − #  # #
Short stature # − # # # # # # #  − −  #    − # #  −
Develop
mental delay
# #  # # # − #  − − − − − − # # − # # − −
Hearing loss − − − − −      − −     # − # #  −
Seizures #   − − − − #  − −  − − − # # −  − − −
Respiratory
problems
# # #   − −  #   − − −    −     
Vascular
calcification
− − − − − − − #  − − − − −  − − − − − − −






MGP mutation IVS2+1G>A − − − c.79C>T IVS1+1G>A*** − − − IVS2+1G>A c.79C>T delE4 IVS1-2A>G − IVS1+1G>A c.2T>C − −
 : present; #: absent; -: unknown, undetermined or unclear. aNot originally described as a Keutel patient. bDetailed information was not reported although cases were said to present all classical Keutel
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and shortening of some of the endochondral bones. Midface
hypoplasia is commonly caused by the premature closure of the
cranial sutures, sometimes in association with the premature
closure of the SOS. However, in Mgp−/− mice, the cranial sutures
are not prematurely fused, but SOS are. It is possible that both
SOS and nasal septum calcification contribute to the observed
midface hypoplasia in both Mgp−/− mice and in the KS patients.
Histological analyses reveal that the continuity of the
prehypertrophic and proliferating cell layers in the growth plates
of the endochondral bones of Mgp−/− mice is disrupted by the
premature deposition of minerals (Murshed et al., 2004). This
phenotype may affect the growth of the long bones, although
most of the Mgp−/− mice die before the full manifestation of
this phenotype. Following a transgenic approach, when vascular
calcification in Mgp−/− mice was prevented by vascular smooth
muscle cell (VSMC)-specific restoration of Mgp expression, the
early lethality was prevented. This tissue-specific rescue model
provided a unique opportunity to examine the ultimate fate of
the growth plates in the absence of MGP; the growth plates
were almost completely lost with age in these mice due to
abnormal deposition of minerals (Murshed et al., 2004). Note that
unlike humans, mice do not show closure of the endochondral
growth plates after puberty and maintain this cartilaginous
tissue throughout the adulthood. As local expression of Mgp
in the VSMCs prevents vascular calcification in Mgp−/− mice,
but not cartilage calcification, chondrocyte-specific expression
of Mgp in Mgp−/− mice prevents cartilage, but not vascular
calcification (Marulanda et al., 2017). This observation suggests
that MGP prevents ECM mineralization locally. Collectively,
further analyses of the traits of these animal models may help us
understanding some of the KS pathologies, such as the shortening
of distal phalanges.
Several early studies suggested that MGP might inhibit
signaling mediated by bone morphogenetic proteins (BMPs).
It was proposed that the loss of MGP in the vascular tissues
induces BMP signaling and trans-differentiation of VSMCs
toward the chondrogenic/osteogenic lineage (Zebboudj et al.,
2002). Although chondrocyte-like cells do appear in the heavily
calcified arteries of Mgp−/− mice, it is now evident that this
alteration of cellular traits is secondary to mineral deposition
(Leroux-Berger et al., 2011; Khavandgar et al., 2014). It is
highly likely that MGP directly prevents mineral deposition
on extracellular protein scaffold. This notion is supported
by two in vivo observations – firstly, the initial mineral
deposition in Mgp−/− arteries occur before any upregulation
of chondrogenic/osteogenic markers, and secondly, gene dose
reduction of a mineral-scaffolding extracellular protein elastin in
Mgp−/− arteries significantly reduces the amount of deposited
minerals (Khavandgar et al., 2014).
A direct role of MGP in the prevention of ECM mineralization
will rely on specific features in its structure. Indeed, two post-
translational modifications – the carboxylation of five glutamic
acid residues (four in mice) by GGCX and phosphorylation
of three N-terminal serine residues by yet unknown kinase(s)
have been thought to be necessary for MGP’s anti-mineralization
function. In a transgenic model, when MGP was overexpressed
in bone, it resulted in a moderate bone mineralization
defect. However, in a follow-up experiment when a mutated
form of MGP lacking its glutamic acid residues undergoing
carboxylation by GGCX was expressed in bone, it failed
to cause any mineralization defect (Murshed et al., 2004).
These experiments suggest a critical role of MGP’s conserved
glutamic acid residues and their post-translational carboxylation
in the skeletal tissues. Until now, no in vivo experiments
have been performed to determine the role of the conserved
serine residues in MGP in its anti-mineralization function.
In vitro studies showed that an N-terminal human MGP
peptide carrying the phosphorylated serine residues prevents
mineral crystal formation (Schurgers et al., 2007; O’Young
et al., 2011). More recently, Parashar et al. demonstrated that
a similar mouse MGP peptide carrying the phosphorylated
serine residues prevents mineral deposition in both cell culture
and cell free models of elastin calcification (Parashar et al.,
2021), while the non-phosphorylated control peptide did
not. The ongoing studies using novel mutations in MGP’s
conserved residues in our laboratories will provide critical
information on how MGP prevents ectopic mineralization
of soft tissues.
CONCLUSION AND PERSPECTIVES
Fifty years of research on Keutel syndrome have clarified both
the phenotype and the genotype of the disease. Distinctive KS
traits (e.g., abnormal cartilage calcification facial features and
brachytelephalangism) can be easily identified through clinical
observation and allow to positively diagnose the disease, while
mutations in MGP gene identified through DNA sequencing will
unequivocally confirm the diagnosis. In this regard, an effort
should be made toward the sequencing of MGP gene in all the
reported cases of KS – so far less than 30% of the KS patients were
genotyped for MGP – to gain insights into a possible link between
the severity of the disease and the type of mutation (Figure 1C).
Although knockout mice have proven their usefulness to clearly
associate a defective matrix Gla protein with the development of
the disease, much remains to be discovered about MGP function
in relation to Keutel syndrome. Currently, the underlying cause
of midface hypoplasia in KS patients and Mgp-/- mice is not
well-understood. It is possible that both nasal septum and
SOS calcification contribute to this trait, however additional
studies will be needed to determine the relative contributions of
these two ectopic calcification events to the abnormal midface
development in KS patients. Further, it is still unknown how
MGP prevents ECM mineralization in cartilage and vascular
tissues, and whether different post-translational modifications
in MGP work in concert or independently to confer its anti-
mineralization function. In this regard, the generation of new
mouse models such as knock-in mice carrying targeted MGP
mutations should provide interesting data on the function of
the different protein domains/functional residues. Similar genetic
approaches can be used to investigate the consequence of the
mutations identified in KS patients. In addition, given the high
level of conservation of MGP among species, the development
of different animal models could contribute to shed further light
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into the mechanism of action of MGP and better understand its
role in the development of this rare disease.
Although prognosis is good in most cases, the health
conditions of KS patients are often far from normal with
symptoms that can be a burden to them and their families. While
reconstructive surgery, angiographic dilatation, antihypertensive
and bronchodilating agents, and antibiotics can be used to treat
some of these symptoms and improve patient condition, others
such as developmental delay, seizures or hearing loss are only
efficiently treated if tackled very early during development, before
ectopic calcifications initiate in the different tissues. In this
regard, gene therapy approaches to restore the normal expression
of MGP, the causal gene for KS, may represent a pertinent
solution for patients suffering from incapacitating symptoms.
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